The immunotherapy advancement targeting malignant blastomas in early childhood

Malignant blastomas develop relentlessly in all functional body organs inflicting severe health ailments in younger children. Malignant blastomas exhibit diverse clinical characteristics in compliance with their emergence in functional body organs. Surprisingly, neither of these preferred treatment...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-02, Vol.13, p.1015115-1015115
Main Authors: Zang, Bolun, Ding, Luyue, Liu, Linlin, Arun Kumar, Senthil, Liu, Wei, Zhou, Chongchen, Duan, Yongtao
Format: Article
Language:English
Subjects:
advanced immunotherapy
childhood
chimeric-antigen based receptor cell therapy
malignant blastomas
monoclonal antibodies
Oncology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignant blastomas develop relentlessly in all functional body organs inflicting severe health ailments in younger children. Malignant blastomas exhibit diverse clinical characteristics in compliance with their emergence in functional body organs. Surprisingly, neither of these preferred treatment types (surgery, radiotherapy, and chemotherapy) showed promise or were effective in treating malignant blastomas among child patients. N ew, innovative immunotherapeutic procedures including monoclonal antibodies and chimeric-antigen based receptor (CAR) cell therapy, coupled with the clinical study of reliable therapeutic targets and immune regulatory pathways targeting malignant blastomas, have attracted the attention of clinicians recently.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1015115